Identification of aldophosphamide as a metabolite of cyclophosphamide in vitro and in vivo in humans
- PMID: 872080
Item in Clipboard
Identification of aldophosphamide as a metabolite of cyclophosphamide in vitro and in vivo in humans
Cancer Res.
1977 Aug.
Abstract
Aldophosphamide (NSC 254), a putative key metabolite of cyclophosphamide, has now been isolated as a cyanohydrin derivative from an incubation mixture of cyclophosphamide with mouse liver microsomes in vitro and from the plasma of a cyclophosphamide-treated patient. The cyanohydrin has been shown to be identical with an authenic synthetic sample by mass spectrometry and combined gas chromatography-mass spectrometry.
Similar articles
-
A biologically active metabolite of cyclophosphamide.Cancer Res. 1973 Apr;33(4):915-8. Cancer Res. 1973. PMID: 4696485 No abstract available.
-
Isolation and identification of a stabilized derivative of aldophosphamide, a major metabolite of cyclophosphamide.Cancer Res. 1974 Nov;34(11):2933-5. Cancer Res. 1974. PMID: 4417999 No abstract available.
-
Quantitation by gas chromatography-chemical ionization mass spectrometry of cyclophosphamide, phosphoramide mustard, and nornitrogen mustard in the plasma and urine of patients receiving cyclophosphamide therapy.Cancer Res. 1978 Feb;38(2):408-15. Cancer Res. 1978. PMID: 620410
-
Approaches to the pharmacokinetics of cyclophosphamide (NSC 26271): Quantitation of metabolites.Cancer Treat Rep. 1976 Apr;60(4):403-8. Cancer Treat Rep. 1976. PMID: 1277214
-
Cyclophosphamide (NSC-26271)-related phosphoramide mustards- recent advances and historical perspective.Cancer Treat Rep. 1976 Apr;60(4):337-46. Cancer Treat Rep. 1976. PMID: 1277209
Cited by
-
The constitutive androstane receptor is a novel therapeutic target facilitating cyclophosphamide-based treatment of hematopoietic malignancies.Blood. 2013 Jan 10;121(2):329-38. doi: 10.1182/blood-2012-06-436691. Epub 2012 Nov 16. Blood. 2013. PMID: 23160467 Free PMC article.
-
Targeting CAR and Nrf2 improves cyclophosphamide bioactivation while reducing doxorubicin-induced cardiotoxicity in triple-negative breast cancer treatment.JCI Insight. 2022 Jun 22;7(12):e153868. doi: 10.1172/jci.insight.153868. JCI Insight. 2022. PMID: 35579950 Free PMC article.
-
The importance of both CYP2C19 and CYP2B6 germline variations in cyclophosphamide pharmacokinetics and clinical outcomes.Br J Clin Pharmacol. 2019 Sep;85(9):1925-1934. doi: 10.1111/bcp.14031. Epub 2019 Jul 22. Br J Clin Pharmacol. 2019. PMID: 31218720 Free PMC article. Review.
-
Effect of liver failure on the pharmacokinetics of cyclophosphamide.Eur J Clin Pharmacol. 1984;26(5):591-3. doi: 10.1007/BF00543491. Eur J Clin Pharmacol. 1984. PMID: 6468474
-
Effect of phenobarbital on plasma levels of cyclophosphamide and its metabolites in the mouse.Br J Cancer. 1978 Aug;38(2):316-24. doi: 10.1038/bjc.1978.204. Br J Cancer. 1978. PMID: 698048 Free PMC article.